446 related articles for article (PubMed ID: 37156098)
1. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD.
Maurer K; Ho VT; Inyang E; Cutler C; Koreth J; Shapiro RM; Gooptu M; Romee R; Nikiforow S; Antin JH; Wu CJ; Ritz J; Soiffer RJ; Kim HT
Blood Adv; 2023 Aug; 7(15):3903-3915. PubMed ID: 37156098
[TBL] [Abstract][Full Text] [Related]
2. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.
Chhabra S; Jerkins JH; Monahan K; Szabo A; Shah NN; Abedin S; Runaas L; Fenske TS; Pasquini MC; Shaw BE; Drobyski WR; Saber W; D'Souza A; Dhakal B; Mohan M; Longo W; Hamadani M
Bone Marrow Transplant; 2024 Mar; 59(3):373-379. PubMed ID: 38177221
[TBL] [Abstract][Full Text] [Related]
3. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT.
Salas MQ; Charry P; Pedraza A; Martínez-Cibrian N; Solano MT; Domènech A; Suárez-Lledó M; Nomdedeu M; Cid J; Lozano M; de-LLobet N; Arcarons J; Rosiñol L; Gutiérrez-García G; Carreras E; Esteve J; Urbano-Ispizua Á; Fernández-Avilés F; Rovira M; Martínez C
Transplant Cell Ther; 2022 Aug; 28(8):489.e1-489.e9. PubMed ID: 35577323
[TBL] [Abstract][Full Text] [Related]
4. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
[TBL] [Abstract][Full Text] [Related]
5. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.
Rappazzo KC; Zahurak M; Bettinotti M; Ali SA; Ambinder AJ; Bolaños-Meade J; Borrello I; Dezern AE; Gladstone D; Gocke C; Fuchs E; Huff CA; Imus PH; Jain T; Luznik L; Rahmat L; Swinnen LJ; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2021 Nov; 27(11):909.e1-909.e6. PubMed ID: 34425261
[TBL] [Abstract][Full Text] [Related]
7. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation.
Mehta RS; Saliba RM; Rondon G; Al-Atrash G; Bashir Q; Hosing CM; Kebriaei P; Khouri I; Nieto Y; Oran B; Popat UR; Qazilbash MH; Ramdial J; Srour SA; Champlin RE; Rezvani K; Shpall EJ; Alousi AM
Transplant Cell Ther; 2022 Oct; 28(10):695.e1-695.e10. PubMed ID: 35902049
[TBL] [Abstract][Full Text] [Related]
8. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Bolaños-Meade J; Hamadani M; Wu J; Al Malki MM; Martens MJ; Runaas L; Elmariah H; Rezvani AR; Gooptu M; Larkin KT; Shaffer BC; El Jurdi N; Loren AW; Solh M; Hall AC; Alousi AM; Jamy OH; Perales MA; Yao JM; Applegate K; Bhatt AS; Kean LS; Efebera YA; Reshef R; Clark W; DiFronzo NL; Leifer E; Horowitz MM; Jones RJ; Holtan SG;
N Engl J Med; 2023 Jun; 388(25):2338-2348. PubMed ID: 37342922
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
[TBL] [Abstract][Full Text] [Related]
10. Post-transplantation Cyclophosphamide-based Graft-versus-host-disease Prophylaxis Compared to Methotrexate-cyclosporine a in Matched-related Allogeneic Hematopoietic Stem Cell Transplantation.
Shouman MT; Mansour OM; El Gammal MM; Abdel-Fattah RM; Samra MA; Elhaddad AM; Maher MA; Mahmoud HK
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):379-387. PubMed ID: 37363983
[TBL] [Abstract][Full Text] [Related]
11. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
Gooptu M; Romee R; St Martin A; Arora M; Al Malki M; Antin JH; Bredeson CN; Brunstein CG; Chhabra S; Fuchs EJ; Ghosh N; Grunwald MR; Kanakry CG; Kekre N; McGuirk JP; McNiece IK; Mehta RS; Mielcarek M; Milano F; Modi D; Reshef R; Solomon SR; Schroeder MA; Waller EK; Inamoto Y; Soiffer RJ; Eapen M
Blood; 2021 Jul; 138(3):273-282. PubMed ID: 34292325
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157
[TBL] [Abstract][Full Text] [Related]
13. Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor.
Sugita J; Kuroha T; Ishikawa J; Eto T; Fukushima K; Yokota I; Akashi K; Taniguchi S; Harada M; Teshima T
Bone Marrow Transplant; 2024 Mar; 59(3):344-349. PubMed ID: 38114645
[TBL] [Abstract][Full Text] [Related]
14. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
15. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
[TBL] [Abstract][Full Text] [Related]
16. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro J; Boumendil A; Finel H; Bramanti S; Castagna L; Blaise D; Dominietto A; Kulagin A; Yakoub-Agha I; Tbakhi A; Solano C; Giebel S; Gulbas Z; López Corral L; Pérez-Simón JA; Díez Martín JL; Sanz J; Farina L; Koc Y; Socié G; Arat M; Jurado M; Bermudez A; Labussière-Wallet H; Villalba M; Ciceri F; Martinez C; Nagler A; Sureda A; Glass B
Transplant Cell Ther; 2024 Feb; 30(2):210.e1-210.e14. PubMed ID: 38043802
[TBL] [Abstract][Full Text] [Related]
17. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
[TBL] [Abstract][Full Text] [Related]
18. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.
Kwon M; Bailén R; Pascual-Cascón MJ; Gallardo-Morillo AI; García Sola A; Balsalobre P; Solán L; Dorado N; Muñoz C; Serrano D; Martínez-Laperche C; Buño I; Anguita J; Díez-Martin JL
Blood Adv; 2019 Nov; 3(21):3351-3359. PubMed ID: 31698447
[TBL] [Abstract][Full Text] [Related]
19. Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical Stem Cell Transplantation.
Tang J; Jensen RR; Bryan B; Hoda D; Hunter BD
Transplant Cell Ther; 2024 Apr; 30(4):438.e1-438.e11. PubMed ID: 38281591
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?
Mehta RS; Saliba RM; Hayase E; Jenq RR; Abraham S; Rashid A; Rondon G; Al-Atrash G; Bashir Q; Hosing CM; Kebriaei P; Khouri I; Marin D; Nieto Y; Olson A; Oran B; Popat UR; Qazilbash MH; Ramdial J; Srour S; Champlin RE; Rezvani K; Shpall EJ; Alousi AM
Transplant Cell Ther; 2022 Aug; 28(8):500.e1-500.e10. PubMed ID: 35662592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]